Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

BRCA2 deletion

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

›

BRCA2 deletion	Ovarian Cancer	BRCA2 deletion	Ovarian Cancer	niraparib Sensitive: A1 - Approval niraparib Sensitive : A1	niraparib Sensitive: A1 - Approval niraparib Sensitive : A1
BRCA2 deletion	Peritoneal Cancer	BRCA2 deletion	Peritoneal Cancer	niraparib Sensitive: A1 - Approval niraparib Sensitive : A1	niraparib Sensitive: A1 - Approval niraparib Sensitive : A1
BRCA2 deletion	Fallopian Tube Cancer	BRCA2 deletion	Fallopian Tube Cancer	niraparib Sensitive: A1 - Approval niraparib Sensitive : A1	niraparib Sensitive: A1 - Approval niraparib Sensitive : A1
BRCA2 deletion	HER2 Negative Breast Cancer	BRCA2 deletion	HER2 Negative Breast Cancer	talazoparib Sensitive: A1 - Approval talazoparib Sensitive : A1	talazoparib Sensitive: A1 - Approval talazoparib Sensitive : A1
BRCA2 deletion	Prostate Cancer	BRCA2 deletion	Prostate Cancer	enzalutamide capsule Sensitive: B - Late Trials enzalutamide capsule Sensitive : B	enzalutamide capsule Sensitive: B - Late Trials enzalutamide capsule Sensitive : B
BRCA2 deletion	Prostate Cancer	BRCA2 deletion	Prostate Cancer	abiraterone acetate Sensitive: B - Late Trials abiraterone acetate Sensitive : B	abiraterone acetate Sensitive: B - Late Trials abiraterone acetate Sensitive : B
BRCA2 deletion	Prostate Cancer	BRCA2 deletion	Prostate Cancer	rucaparib Sensitive: C3 – Early Trials rucaparib Sensitive : C3	rucaparib Sensitive: C3 – Early Trials rucaparib Sensitive : C3
BRCA2 deletion	Ovarian Cancer	BRCA2 deletion	Ovarian Cancer	rucaparib Sensitive: C3 – Early Trials rucaparib Sensitive : C3	rucaparib Sensitive: C3 – Early Trials rucaparib Sensitive : C3
BRCA2 deletion	Prostate Cancer	BRCA2 deletion	Prostate Cancer	olaparib Sensitive: C3 – Early Trials olaparib Sensitive : C3	olaparib Sensitive: C3 – Early Trials olaparib Sensitive : C3
BRCA2 deletion	Ovarian Cancer	BRCA2 deletion	Ovarian Cancer	bevacizumab Sensitive: C3 – Early Trials bevacizumab Sensitive : C3	bevacizumab Sensitive: C3 – Early Trials bevacizumab Sensitive : C3
BRCA2 deletion	Ovarian Serous Adenocarcinoma	BRCA2 deletion	Ovarian Serous Adenocarcinoma	bevacizumab Sensitive: C3 – Early Trials bevacizumab Sensitive : C3	bevacizumab Sensitive: C3 – Early Trials bevacizumab Sensitive : C3
BRCA2 deletion	Soft Tissue Sarcoma	BRCA2 deletion	Soft Tissue Sarcoma	ifosfamide + pegylated liposomal doxorubicin Resistant: C3 – Early Trials ifosfamide + pegylated liposomal doxorubicin Resistant : C3	ifosfamide + pegylated liposomal doxorubicin Resistant: C3 – Early Trials ifosfamide + pegylated liposomal doxorubicin Resistant : C3
BRCA2 deletion	Squamous Cell Skin Cancer	BRCA2 deletion	Squamous Cell Skin Cancer	pembrolizumab Sensitive: C4 – Case Studies pembrolizumab Sensitive : C4	pembrolizumab Sensitive: C4 – Case Studies pembrolizumab Sensitive : C4
BRCA2 deletion	Prostate Cancer	BRCA2 deletion	Prostate Cancer	ACR-368 Sensitive: D – Preclinical ACR-368 Sensitive : D	ACR-368 Sensitive: D – Preclinical ACR-368 Sensitive : D